CRDF Similar Chart Price Prediction
The price of CRDF is predicted to go up -4.64%, based on the high correlation periods with KOPN. The similarity of these two price pattern on the periods is 93.76%.
CRDF
KOPN
Down: -4.64%Similarity: 93.76%
CRDF Revenue Forecast
CRDF EPS Forecast
CRDF FAQs
What is CRDF revenue forecast for next quarter？
CRDF Analyst's Forecast
Joseph Catanzaro
Piper Sandler
Buy
2024-12-13
Price Target
$7 → $10
Upside
+155.1%
Piper Sandler raised the firm's price target on Cardiff Oncology to $10 from $7 and keeps an Overweight rating on the shares. The company reported initial data from its ongoing randomized Phase II trial of onvansertib in RAS-mutated mutated metastatic colorectal cancer and the early randomized dataset seems to clearly support the hypothesis that onvansertib on top of chemotherapy provides meaningful clinical benefit, the analyst tells investors in a research note. Piper sees the data as meaningfully derisking."
